In a nutshell This study investigated whether the neutrophil-to-lymphocyte ratio (NLR) can be used to predict clinical outcomes in metastatic prostate cancer. Researchers concluded that the NLR can help in determining clinical outcomes in metastatic prostate cancer. Some background Neutrophils are cells that are involved in inflammation (reaction...
Read More
In a nutshell This study examined the effects of enzalutamide (Xtandi) with respect to the site of metastatic castration-resistant prostate cancer. Researchers concluded that enzalutamide is a safe and effective treatment for all sites of metastases studied. Some background When prostate cancer spreads outside of the prostate (also called...
Read More
In a nutshell The authors reviewed the effectiveness of combination therapy of vemurafenib (Zelboraf) and cobimetinib (Cotellic) for the treatment of BRAF-mutated advanced melanoma. The study concluded that a combination treatment with vemurafenib and cobimetinib is an effective option in BRAF-mutant melanoma that...
Read More
In a nutshell The authors evaluated the effect of combination treatment of nivolumab (Opdivo) and a type of radiation therapy for the treatment of melanoma spread to the brain. The authors found out that this radiation therapy was well tolerated and produced better survival in melanoma patients who also received nivolumab. Some background In...
Read More
In a nutshell This study examined abiraterone acetate (Zytiga) as a treatment option for older men with metastatic castration-resistant prostate cancer. Researchers concluded that abiraterone acetate improves overall survival in younger as well as older men with metastatic castration resistant prostate cancer. Some background...
Read More
In a nutshell This study investigated the presence of the gene TMPRSS2-ERG in patients with metastatic castration-resistant prostate cancer on treatment outcome with taxane-based chemotherapy. Researchers reported that TMPRSS2-ERG, as identified by blood tests, is a reliable predictors of treatment success with taxane-based chemotherapy. Some...
Read More
In a nutshell This phase 2 study recruiting in New York aims to determine the effectiveness of regorafenib (Stivarga) in patients with metastatic colorectal cancer. The main outcome will be time to disease progression. The details The standard treatment for metastatic (spread to other areas of the body) colorectal cancer is a combination of...
Read More
In a nutshell This study examined personalized peptide vaccine (PPV) immunotherapy in the treatment of advanced metastatic prostate cancer. Researchers reported that patients treated with PPV showed delayed disease progression and increased overall survival. Some background Immunotherapy has recently been under intense investigation as a possible...
Read More
In a nutshell The authors assessed the effect of vemurafenib (Zelboraf) in metastatic (spread to other areas of the body) melanoma patients prior to surgery. The authors found that surgery to remove metastatic tumors is safe and effective during or just after treatment with vemurafenib. Some background In advanced melanoma (stages 3 to...
Read More
In a nutshell The authors evaluated the effectiveness of combination therapy of dabrafenib (Tafinlar) and trametinib (Mekinist) in advanced melanoma patients with mutations (permanent changes) in BRAF genes. The authors found out that the combination therapy improved overall survival (time from treatment until death from any cause). Some background...
Read More
In a nutshell The authors aimed to determine the benefit of sequencing docetaxel (Taxotere) and abiraterone (Zytiga) treatment to improve progression-free survival (patients who did not experience cancer growth after treatment) in patients with metastaic (cancer that has spread) hormone-resistant (cancer that does not respond to hormone...
Read More
In a nutshell This trial assessed the effectiveness of combining a TG4010, a type of immunotherapy, with chemotherapy for non-small-cell lung cancer. It also examined whether TG4010 was more effective in patients with a low level of certain immune cells, called triple positive activated lymphocytes (TrPAL). The study concluded that TG4010 was...
Read More
